tbuckley/cabot-search huggingface dataset:
Coexistence of pyoderma gangrenosum and Cushing’s disease: a paradoxical association?
Authors: B. De Silva, V.R. Doherty
Journal: British Journal of Dermatology (2000)

Journal Article Coexistence of pyoderma gangrenosum and Cushing’s disease: a paradoxical association? Get access B. De Silva, B. De Silva Department of Dermatology, The Royal Infirmary, Lauriston Place, Lauriston Building, Edinburgh EH3 9YW, Scotland, U.K. *Department of Dermatology, Victoria Hospital, Kirkcaldy, Scotland, U.K. Search for other works by this author on: Oxford Academic Google Scholar V.R. Doherty V.R. Doherty Department of Dermatology, The Royal Infirmary, Lauriston Place, Lauriston Building, Edinburgh EH3 9YW, Scotland, U.K. *Department of Dermatology, Victoria Hospital, Kirkcaldy, Scotland, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 5, 1 May 2000, Pages 1051–1052, https://doi.org/10.1046/j.1365-2133.2000.03499.x Published: 01 May 2000
Cloned chickens to help fight cancer.
Authors: Bryan Christie
Journal: BMJ (2000)

The scientists who created Dolly the sheep are planning to clone a hen that can lay “golden” eggs that are rich in proteins to fight human cancer.

They have announced a project aimed at breeding flocks of genetically altered chickens that will act as living pharmaceutical factories, producing anticancer treatments in their eggs.

The scientists at the Roslin Institute near Edinburgh are confident of success and said that their work will result in a new generation of cancer treatments, produced much more cheaply and easily, with the potential of extending the benefit to many more patients with …
Is Paradoxical Low Gradient Severe Aortic Stenosis With Preserved Ejection Fraction Associated With a Poor Prognosis in Elderly Patients
Authors: Agnes Pasquet, Jean-Louis Vanoverschelde, David Vancraeynest, Amin Amraoui, Stéphanie Seldrum, Sophie F. Piérard, Bernhard Gerber
Journal: Circulation (2009)
Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose
Authors: G R Dagenais, H C Gerstein, R Holman, A Budaj, A Escalante, T Hedner, M Keltai, E Lonn, S McFarlane, M McQueen, K Teo, P Sheridan, J Bosch, J Pogue, S Yusuf
Journal: Diabetes Care (2008)

Impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are risk factors for diabetes, cardiovascular disease (CVD), and kidney disease. We determined the effects of ramipril and rosiglitazone on combined and individual CVD and renal outcomes in people with IGT and/or IFG in the Diabetes REduction Assessment With ramipril and rosiglitazone Medication (DREAM) trial.A total of 5,269 people aged >or=30 years, with IGT and/or IFG without known CVD or renal insufficiency, were randomized to 15 mg/day ramipril versus placebo and 8 mg/day rosiglitazone versus placebo. A composite cardiorenal outcome and its CVD and renal components were assessed during the 3-year follow-up.Compared with placebo, neither ramipril (15.7% [412 of 2,623] vs. 16.0% [424 of 2,646]; hazard ratio [HR] 0.98 [95% CI 0.84-1.13]; P = 0.75) nor rosiglitazone (15.0% [394 of 2,635] vs. 16.8% [442 of 2,634]; 0.87 [0.75-1.01]; P = 0.07) reduced the risk of the cardiorenal composite outcome. Ramipril had no impact on the CVD and renal components. Rosiglitazone increased heart failure (0.53 vs. 0.08%; HR 7.04 [95% CI 1.60-31.0]; P = 0.01) but reduced the risk of the renal component (0.80 [0.68-0.93]; P = 0.005); prevention of diabetes was independently associated with prevention of the renal component (P < 0.001).Ramipril did not alter the cardiorenal outcome or its components. Rosiglitazone, which reduced diabetes, also reduced the development of renal disease but not the cardiorenal outcome and increased the risk of heart failure.
IL-2 is a critical regulator of group 2 innate lymphoid cell function during pulmonary inflammation
Authors: Ben Roediger, Ryan Kyle, Szun S Tay, Andrew J Mitchell, Holly A Bolton, Thomas V Guy, Sioh-Yang Tan, Elizabeth Forbes-Blom, Philip L Tong, Yasmin Köller, Elena Shklovskaya, Makio Iwashima, Kathy D McCoy, Graham Le Gros, Barbara Fazekas de St Groth, Wolfgang Weninger
Journal: Journal of Allergy and Clinical Immunology (2015)
Abstract 1869: Using Nanoparticle Tracking Analysis (NTA) to characterize cellular microvesicles
Authors: Sonja Capracotta, Pauline Carnell, Andrew Malloy, Patrick Hole, Bob Carr
Journal: Cancer Research (2014)

Abstract Cellular microvesicles (100 nm-1µm) are shed into the circulation from many different cell types including; platelets, erythrocytes and endothelial cells. They have major potential as novel biomarkers as they have been shown to be implicated in a multitude of pathological conditions. However, developments in this area are constrained by limitations in the technology available for their measurement. Nanoparticle Tracking Analysis (NTA) (NanoSight Ltd, Amesbury) offers the potential to both enumerate and speciate (through fluorescent markers) these microparticles in a rapid manner. In this method a laser beam passes through a suspension at a low angle. The particles scatter light which is collected onto a CCD (or sCMOS) camera by a microscope-type configuration. Particles between 10-2000 nm are tracked individually and their diffusion coefficient, and therefore size, calculated directly from their speed. Therefore, this characterization method gives a direct measurement of the concentration and size distribution of the particles in the field of view. If the particles are fluorescently labelled, then the concentration and size distribution are those of the labelled particles only, allowing a proportion of labelled particles to be calculated. However, this requires a combination of aspects to be identified and optimised during the process. This talk will look at some of the challenges and considerations that need to be taken during the protocol development and measurement. It will also review the application of the technique in this field, compare and contrast it to other applicable technologies such as various forms of electron microscopy (EM) and to flow cytometry. Citation Format: Sonja Capracotta, Pauline Carnell, Andrew Malloy, Patrick Hole, Bob Carr. Using Nanoparticle Tracking Analysis (NTA) to characterize cellular microvesicles. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1869. doi:10.1158/1538-7445.AM2014-1869
Palisaded encapsulated neuroma (solitary circumscribed neuroma) of the glans penis
Authors: M. Navarro, J. Vilata, C. Requena, A. Aliaga
Journal: British Journal of Dermatology (2000)

Journal Article Palisaded encapsulated neuroma (solitary circumscribed neuroma) of the glans penis Get access M. Navarro, M. Navarro Servicio de Dermatología, Hospital General Universitario de Valencia, Av Tres Cruces s/n, 46014 Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar J. Vilata, J. Vilata Servicio de Dermatología, Hospital General Universitario de Valencia, Av Tres Cruces s/n, 46014 Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar C. Requena, C. Requena Servicio de Dermatología, Hospital General Universitario de Valencia, Av Tres Cruces s/n, 46014 Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar A. Aliaga A. Aliaga Servicio de Dermatología, Hospital General Universitario de Valencia, Av Tres Cruces s/n, 46014 Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 5, 1 May 2000, Pages 1061–1062, https://doi.org/10.1046/j.1365-2133.2000.03507.x Published: 01 May 2000
Medicine and Human Welfare
Authors: Henry Ernest Sigerist
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
744. Genetic Structure of Adeno-Associated Virus DNA in Human Tissues
Authors: Bruce C. Schnepp, Chun-Liang Chen, Ryan L. Jensen, K. Reed Clark, Philip R. Johnson
Journal: Molecular Therapy (2004)

Background. Infection with wild-type adeno-associated virus (AAV) is common in humans. However, very little is known about the in vivo biology of natural AAV infection. Because AAV DNA can integrate in a site-specific manner on chromosome 19 in cultured cells, it has been assumed (but not shown) that it integrates similarly during the course of natural infection. To confirm this assumption, we tested human tissue samples for the presence of AAV DNA, and when present, examined the specific form of the viral DNA.
OPISTHORCHIASIS WITH PULMONARY INVOLVEMENT
Authors: B PRIJYANONDA, S TANDHANAND
Journal: Annals of Internal Medicine (1961)

Case Reports1 April 1961OPISTHORCHIASIS WITH PULMONARY INVOLVEMENTBANYAT PRIJYANONDA, M.D., SUNTHORN TANDHANAND, M.D.BANYAT PRIJYANONDA, M.D.Search for more papers by this author, SUNTHORN TANDHANAND, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-54-4-795 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe first clinical description of opisthorchiasis in Thailand was made by Prommas in 1927.1Pradatsundarasar in 19502recorded 31 instances of liver fluke infestation due toOpisthorchis viverriniobserved between 1945 and 1949 in the Department of Pathology of the Siriraj Hospital. In 1952 and 1953 Sadun and Vajrasthira3, 4, 5reported the prevalence of opisthorchiasis in the northeastern part of Thailand, and estimated that not less than 1,500,000 among the Thai population of 18,000,000 in 1952 harbored the parasite. Viranuvatti and Mettiyawongse in 19536reported the concurrence of opisthorchiasis with carcinoma of the liver in two patients. In 1955...Bibliography1. Prommas C: Report of a case of Opisthorchis felineus in Siam. Ann. Trop. Med. Parasit. 21: 9, 1927. CrossrefGoogle Scholar2. Pradatsundarasar A: Some observations on liver fluke infestation. Siriraj Hosp. Gaz. 2: 379, 1950. Google Scholar3. SadunVajrasthira EHS: Intestinal helminthic infections in Northeast Thailand. J. Parasit. 34: 22, Section 2 (Aug.) 1952. Google Scholar4. Sadun EH: Intestinal helminthic infections in Thailand. J. Med. Ass. Thailand 36: 193, 1953. Google Scholar5. Sadun EH: Helminthic diseases in Thailand. Fifth International Congress on Tropical Medicine and Malaria, Istanbul, 1953. Google Scholar6. ViranuvattiMettiyawongse VS: Observation on two cases of opisthorchiasis in Thailand. Ann. Trop. Med. Parasit. 47: 291, 1953. CrossrefMedlineGoogle Scholar7. ViranuvattiKashemsantBhamarapravati VDN: Retention cyst of liver caused by opisthorchiasis associated with carcinoma. Amer. J. Gastroent. 23: 442, 1955. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Dhonburi,*Received for publication March 8, 1960.From the Department of Medicine, Siriraj Hospital, Dhonburi, Thailand.Requests for reprints should be addressed to Banyat Prijyanonda, M.D., Department of Medicine, Siriraj Hospital, Dhonburi, Thailand. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInfectious diseasesParasitic InfectionsAmoebiasis and other parasitic diseases of the liverParasitic InfectionsParasitäre LungenkrankheitenCase 26-1974Parasites of man and domestic animals in Vietnam, Thailand, Laos, and Cambodia 1 April 1961Volume 54, Issue 4Page: 795-799KeywordsBileClinical pathologyGratitudeHospital medicineLesionsLiverThorax Issue Published: 1 April 1961 PDF downloadLoading ...
Fas-Mediated Modulation of Bcr/Abl in Chronic Myelogenous Leukemia Results in Differential Effects on Apoptosis
Authors: Carmine Selleri, Jaroslaw P. Maciejewski, Fabrizio Pane, Luigia Luciano, Anna Maria Raiola, Ilaria Mostarda, Francesco Salvatore, Bruno Rotoli
Journal: Blood (1998)
82. Adaptation of a Lentiviral Vector Producer Cell Line to Reduced-Serum, Suspension Culture for Large Scale Production
Authors: James E. Miskin, Holger Roehl, Denise Westfall, Jonathan Rohll, Daniel Chipchase, Douglas Jolly, Susan M. Kingsman, Kyriacos A. Mitrophanous
Journal: Molecular Therapy (2004)

The ability of lentiviral-based vectors to integrate into non-dividing cells such as neuronal cells has been exploited to correct a number of disease models. Using vectors based on the equine infectious anaemia virus (EIAV) we have previously reported the correction of an animal model of Parkinson's disease (Azzouz et al. J Neurosci. 2002 Dec 1;22(23):10302–12). To use such vectors in the clinic each manufactured lot must be tested and demonstrated to be free of replication competent lentivirus (RCL). We have designed the vectors in such a way to limit the possibility of homologous recombination taking place; the vector genome contains only 824 nt of EIAV sequence with no coding regions; all the accessory genes have been removed entirely from the system; the gag/pol sequence has been codon optimised and a heterologous envelope is used (VSV-G). However, there is still the formal possibility of some form of recombination leading to the generation of an RCL. We have therefore developed an RCL assay based on the property common to all members of the Retroviradae family, namely the presence of reverse transcriptase (RT). RT activity can be detected by a sensitive assay: Product Enhanced Reverse Transcriptase (PERT). The test article is passaged on human cells to amplify any replicating entity and then a PERT assay is carried out on the supernatant. A typical set of assay results will be presented.
TRAUMATIC THROMBOPHLEBITIS DURING INTRA-ARTERIAL HISTAMINE THERAPY
Authors: L E WOLD
Journal: Annals of Internal Medicine (1950)

Case Reports1 May 1950TRAUMATIC THROMBOPHLEBITIS DURING INTRA-ARTERIAL HISTAMINE THERAPYLESTER E. WOLD, M.D.LESTER E. WOLD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-32-5-987 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe purpose of this presentation is to report a complication observed while giving histamine intra-arterially in the treatment of peripheral vascular disease. The treatment of obliterative arterial disease described by Mufson1has a definite appeal because it may be done as an office procedure. Before this method of therapy was suggested, there was little that could be offered the patient with obliterative arterial disease except in larger centers where long periods of treatment on Saunder's bed, sympathectomy, or physical therapy could be given. Such regimes of therapy are frequently so costly as to be beyond the reach of many patients...Bibliography1. Mufson I: A new treatment for the relief of obliterative disease of peripheral arteries, Ann. Int. Med. 29: 903, 1948. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Fargo, North Dakota*Received for publication October 7, 1949. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byKrankheiten der Gefäße 1 May 1950Volume 32, Issue 5Page: 987-988KeywordsHistaminePeripheral vascular diseaseSympathectomy ePublished: 1 December 2008 Issue Published: 1 May 1950 PDF downloadLoading ...
Abstract 18994: Endothelial Dysfunction Predicts Atrial Arrhythmia Recurrence Following Pulmonary Vein Isolation in Patients ≤ 60 Years Old
Authors: Yasushi Matsuzawa, Mahmoud Suleiman, Raviteja R Guddeti, Taek-Geun Kwon, David O Hodge, Lilach O Lerman, Paul A Friedman, Amir Lerman
Journal: Circulation (2014)

Background: Endothelial dysfunction may be associated with atrial fibrillation (AFib). However, available evidence concerning endothelial dysfunction in patients with AFib undergoing left atrial ablation is limited. The purpose of this study was to investigate whether left atrial ablation for AFib affects endothelial dysfunction, and whether endothelial dysfunction predicts atrial arrhythmia recurrence after catheter ablation. Methods: We prospectively studied 92 patients (age 57 ± 10 years old, 78% males) who underwent left atrial ablation for the treatment of refractory paroxysmal or persistent AFib. Endothelial function was non-invasively evaluated before and at 3 months after ablation, using reactive hyperemia-peripheral arterial tonometry (RH-PAT). Logarithmic value of RH-PAT index (Ln_RHI) was calculated accordingly. Patients were followed for 3 months for atrial arrhythmia recurrence, and the optimal cut-off value of Ln_RHI to predict it was defined by Youden index. Results: Left atrial ablation fo...
Publishers withdraw 2500 journals from free access scheme in Bangladesh
Authors: Zosia Kmietowicz
Journal: BMJ (2011)

Five publishers have withdrawn free access to more than 2500 health and biomedical online journals from institutions in Bangladesh. One research leader has described the situation as “very discouraging.” 

From 4 January Elsevier Journals withdrew access in Bangladesh to 1610 of its publications, including the Lancet stable of journals, which had been available through the World Health Organization’s Health Inter-Network for Access to Research Initiative (HINARI) programme. HINARI was set up in 2002 to enable not for profit institutions in developing countries to …
Diet and Colon Cancer
Authors: Robert S. Bresalier, Young S. Kim
Journal: New England Journal of Medicine (1985)

Cancer of the colon and rectum is a major cause of morbidity and mortality in Western society. In the United States colorectal cancer is the second most common form of cancer in males and the third most common in females, with 138,000 new cases and 60,000 related deaths estimated for 1985. Colon or rectal cancer eventually develops in approximately 6 per cent of the American population, and 6 million Americans who are alive today will die of it. Despite the obvious importance of colorectal cancer and a voluminous body of scientific literature on the subject, our understanding of the cause . . .
Detecting Bladder Cancer
Authors: Rebecca Voelker
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A novel alkylateing agent, glufosfamide, enhances activity of gemcitabine in models of pancreatic cancer
Authors: William S. Ammons, Jin-Wei Wang, Zhijian Yang, Robert M. Hoffman, George F. Tidmarsh, Alan Colowick
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4738 

Glufosfamide is an alkylating agent, consisting of isophosforamide mustard conjugated to glucose, that is currently in clinical studies of pancreatic cancer as second line therapy and in combination with gemcitabine. We studied the effects of glufosfamide in combination with gemcitabine in several preclinical in vitro and in vivo models of pancreatic cancer. In a proliferation assay, both glufosfamide and gemcitabine inhibited growth of types of pancreatic cells, MiaPaCa-2 and Hst766; but the combination of the two agents provided greater effects. Similarly, apoptosis of MiaPaCa-2 cells, measured by FACS, was enhanced by combination of the two drugs compared to treatment with either drug alone. Glufosfamide alone, dosed IV daily for two weeks, significantly inhibited the growth of red fluorescent protein-expressing MiaPaCa-2 tumors in an orthotopic nude mouse model in a dose-dependent manner (10-100 mg/kg) and significantly increased the time to 50% survival. Combining glufosfamide (30 mg/kg) with gemcitabine resulted in significantly enhanced inhibition of tumor growth and significantly prolonged survival. Immunohistochemistry of pancreatic tumors removed from mice after two weeks of treatment revealed that both glufosfamide alone and gemcitabine alone significantly increased the levels of apoptosis, measured by the TUNEL stain, and significantly reduced proliferation, measured by PCNA staining. Combined treatment resulted in significantly greater apoptosis than treatment with either agent alone. No effects on microvessel density, measured by anti-CD31 staining, were observed. The results of these preclinical studies demonstrate that combined use of the alkylating agent glufosfamide and the DNA synthesis inhibitor gemcitabine provide greater benefit than either agent alone and should be useful in the clinical treatment of pancreatic carcinoma.